A conference call will be held today, Wednesday, October 22, 5:00 p.m. E.D.T. DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) announced today results from its Phase IIB clinical trial to compare the ...

LEVULAN KERASTICK offers patients and health care practitioners a treatment option with a well-established safety and efficacy profile that can prevent the progression of actinic keratoses into skin ...

June 1, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for aminolevulinic acid HCl in combination with photodynamic therapy for the treatment of esophageal ...

PRESCOTT, Ariz. -- Firefighters "fight fire with fire" to stop spreading. Dermatologists have a similar technique - they "sunburn" patients to prevent precancerous skin lesions called actinic ...

Says FDA did not grant orphan status to Levulan therapy Levulan developed for prevention of skin cancer Co plans to close its SOTR clinical program Shares plunge 18 pct Aug 6 (Reuters) - DUSA ...

SAN FRANCISCO (CBS.MW) -- DUSA Pharmaceuticals said Monday that it has signed a clinical trial agreement with the U.S. Division of Cancer Prevention's National Cancer Institute. The agreement is for ...

Co announces that the Korea Food and Drug Administration has approved Levulan Kerastick for Photodynamic Therapy for the treatment of actinic keratoses through its marketing partner Daewoong ...

Shares of Dusa Pharmaceuticals were hammered by the news that the developer is dropping development of its Levulan Photodynamic Therapy for moderate to severe acne it flunked a mid-stage trial. Its ...

Topical photodynamic therapy (PDT) which employs 5-aminolevulinic acid (ALA) introduced by Kennedy et al. [1] received approval from the US Food and Drug Administration for the treatment of actinic ...

Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis and squamous cell carcinoma, yet large ...